Tylosin grams/ton	Combination in grams/ton	Indications for use	Limitations	Sponsor *
*		* *	* *	
(ix) 8 to 10	Monensin, 10 to 40 plus melengestrol, 0.25 to 2.0.	Heifers fed in confinement for slaughter: For reduction of inci- dence of liver abscesses caused by <i>Fusobacterium necrophorum</i> and <i>Arcanobacterium</i> (<i>Actinomyces</i>) pyogenes; for pre- vention and control of coccidiosis caused by <i>Eimeria bovis</i> and <i>E.</i> <i>zuernii</i> , and for increased rate of weight gain, improved feed effi- ciency, and suppression of estrus (heat).	Feed continuously as sole ration to heifers at a rate of 0.5 to 2 pounds per head per day to provide 0.25 to 0.5 mg/head/day melengestrol acetate and 0.14 to 0.42 mg monensin/lb body weight per day, depending on the severity of the coccidiosis challenge, up to 480 mg/head/day and 60 to 90 mg/ head/day tylosin. The melengestrol acetate portion of this Type C medicated feed must be mixed into the complete feed containing 10 to 40 g/ton monensin and 8 to 10 g/ton tylosin at feeding into the amount of complete feed consumed by an animal per day. A with-drawal time has not been established for pre-ruminating calves. Do not use in calves to be processed for veal. Tylosin provided by No. 016592 or 058198; melengestrol provided by No. 016592 or 058198; melengestrol provided by No. 016592 or 058198; melengestrol provided by No. 054771 or 058198 in § 510.600(c) of this chapter. See §§ 558.342(d) and 558.355(d).	016592 054771 058198
*	*	* *	* *	*

■ 66. In § 558.635, revise paragraph (e)(1)(iv) to read as follows:		§ 558.635 Virginiamycin. * * * * * *		(e) * * * (1) * * *		
Virginiamycin grams/ton	Combination in grams/ton * Diclazuril, 0.91	Indications for use		Limitations		Sponsor
* (iv) 20		Clostridium perf	tis caused by fringens suscep- mycin; and for of coccidiosis	use in hens prod	* the sole ration. Do not ucing eggs for human provided by No. 058198 his chapter.	* 058198
		necatrix, E. brunetti, E. mit E. maxima. Be is effective aga late in its life c intestinal lesic present for a sh fection. Diclazur	acervulina, E. is (mivati), and cause diclazuril inst E. maxima ycle, subclinical ons may be ort time after in-			
*	*	studies to rescores and im ance and health lenged with <i>E. n</i>	prove perform- h of birds chal-	*	*	*

* * * **ACTION:** Notification of withdrawal. DEPARTMENT OF HEALTH AND HUMAN SERVICES Dated: March 25, 2020. SUMMARY: The Food and Drug Lowell J. Schiller, Food and Drug Administration Administration (FDA) is withdrawing Principal Associate Commissioner for Policy. approval of eight new animal drug [FR Doc. 2020-06688 Filed 3-30-20; 8:45 am] 21 CFR Parts 520, 522, and 526 applications (NADAs) at the sponsor's request because the products are no BILLING CODE 4164-01-P [Docket No. FDA-2019-N-0002] longer manufactured or marketed. New Animal Drugs; Withdrawal of

Approval of New Animal Drug

Applications

DATES: Withdrawal of approval is effective March 30, 2020

FOR FURTHER INFORMATION CONTACT: Sujaya Dessai, Center for Veterinary Medicine (HFV–212), Food and Drug

Administration, 7519 Standish Pl., Rockville, MD 20855, 240-402-5761, sujaya.dessai@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Norbrook Laboratories, Ltd., Station Works, Newry BT35 6JP, Northern Ireland, has requested that FDA withdraw approval

of the NADAs listed in the following table because the products are no longer manufactured or marketed:

File No.	Product name		
055–056	PRINCILLIN (ampicillin trihýdrate) Soluble Powder PRINCILLIN (ampicillin trihýdrate) Bolus PRINCILLIN "125" For Oral Suspension BOVICLOX (cloxacillin benzathine) Dihýdrostreptomycin (dihýdrostreptomycin sulfate) JETPEN (penicillin G benzathine and penicillin G procaine) Aqueous Suspension	520.90e. 520.90f. 520.90d. 526.464b. 522.650. 522.1696a.	

Therefore, under authority delegated to the Commissioner of Food and Drugs and in accordance with § 514.116 Notice of withdrawal of approval of application (21 CFR 514.116), notice is given that approval of NADAs 055-036, 055-050, 055-056, 055-061, 055-068, 065-013, 065-493, and 065-500, and all supplements and amendments thereto, is withdrawn, effective March 30, 2020.

Elsewhere in this issue of the Federal Register, FDA is amending the animal drug regulations to reflect the voluntary withdrawal of approval of these applications.

Dated: March 25, 2020.

Lowell J. Schiller,

Principal Associate Commissioner for Policy. [FR Doc. 2020-06689 Filed 3-30-20; 8:45 am] BILLING CODE 4164-01-P

DEPARTMENT OF DEFENSE

Department of the Navy

32 CFR Part 716

[Docket ID: USN-2019-HQ-0016]

RIN 0703-AB23

Death Gratuity

AGENCY: Department of the Navy (DON), DoD.

ACTION: Final rule.

SUMMARY: This final rule removes the Department of the Navy (DON) regulation requiring the Secretary of the Navy to pay a death gratuity between \$800 and \$3,000 upon the death of a member of the naval service while on active duty, active duty for training, or inactive duty training. That benefit is enumerated in both U.S. Code and the Department of Defense (DoD) Financial Management Regulation. The DoD and DON have robust procedures for responding to the death of a service member. This part has been determined to be duplicative of statute and internal policy, thus it should be removed from the CFR.

DATES: This rule is effective on April 1, 2020.

FOR FURTHER INFORMATION CONTACT: CDR Dave Melson at 703-697-1311.

SUPPLEMENTARY INFORMATION: 32 CFR part 716, "Death Gratuity," last updated on May 2, 1979 (44 FR 25647), contains information regarding DON payments of death gratuity. The Department of Defense publishes the policies, process and requirements around death gratuity payments in Chapter 36 of Volume 7A of the Financial Management Regulation (DoD 7000.14-R was updated March 2018 and is available at https:// comptroller.defense.gov/Portals/45/ documents/fmr/Volume_07a.pdf). Additionally, 10 U.S. Code 1475-1480 captures all current guidance related to the death gratuity. It has been determined that publication of this CFR part removal for public comment is impracticable, unnecessary, and contrary to public interest since this subject matter is already addressed in statute and by internal DoD policies and procedures that are publicly available on the Department's website.

This rule is not significant under Executive Order (E.O.) 12866, "Regulatory Planning and Review." Therefore, E.O. 13771, "Reducing Regulation and Controlling Regulatory Costs" does not apply.

Removal of this part supports a recommendation of the DoD Regulatory Reform Task Force.

List of Subjects in 32 CFR Part 716

Military personnel.

PART 716—[REMOVED]

■ Accordingly, by the authority of 5 U.S.C. 301, 32 CFR part 716 is removed. Dated: March 26, 2020.

D.J. Antenucci,

Commander, Judge Advocate General's Corps, U.S. Navy, Federal Register Liaison Officer. [FR Doc. 2020-06694 Filed 3-31-20; 8:45 am] BILLING CODE 3810-FF-P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 52

[EPA-R04-OAR-2019-0294; FRL-10007-17–Region 4]

Air Plan Approval; Tennessee: Chattanooga NSR Reform

AGENCY: Environmental Protection Agency (EPA). **ACTION:** Final rule.

SUMMARY: The Environmental Protection Agency (EPA) is finalizing approval of revisions to the Tennessee State Implementation Plan (SIP) submitted through two letters dated June 25, 2008, and September 12, 2018. The SIP revisions were submitted by the **Tennessee Department of Environment** and Conservation (TDEC) on behalf of the Chattanooga/Hamilton County Air Pollution Control Bureau and modify the Prevention of Significant Deterioration (PSD) regulations in the Chattanooga portion of the Tennessee SIP to address changes to the federal new source review (NSR) regulations in recent years for the implementation of the national ambient air quality standards (NAAQS). Additionally, the SIP revisions include updates to Chattanooga's regulations of nitrogen oxides (NO_x) and other miscellaneous typographical and administrative updates. This action is being taken pursuant to the Clean Air Act (CAA or Act).

DATES: This rule is effective May 1, 2020.